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Abstract: We performed an analysis of prospectively-acquired cross sectional data on 106 
Parkinson disease (PD) patients who underwent comprehensive neuropsychological testing and 
the Uniﬁ  ed Parkinson Disease Rating Scale (UPDRS) motor scale. A signiﬁ  cant correlation 
between the UPDRS motor and neuropsychological tests in all cognitive domains except for 
general intelligence and visuo-spatial function was seen. In this study, cognitive decline within 
this PD cohort correlated with motor impairment but not disease duration. Our ﬁ  ndings suggest 
that overall cognitive impairment (except visuospatial dysfunction) may track motor progression 
in PD more than duration of disease. Longitudinal studies are needed to conﬁ  rm our results.
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Introduction
It has been previously thought that dementia occurred in 20%–30% of Parkinson 
disease (PD) patients, usually at the later stage of their illness. However, recent long 
term epidemiological studies reported the prevalence rate of dementia in PD closer to 
50% (Hely et al 2005). Others have reported that some form of cognitive decline affects 
nearly 80% of PD patients (Aarsland et al 2003). The relative risk for the development 
of dementia in PD has been reported as being between 1.7 to 5.9 (Marder et al 1995; 
Aarsland et al 2001; Hobson et al 2004).
We hypothesize that cognitive dysfunction in PD is progressive, actually begins 
early in the course, affects most patients, and tracks their motor impairment. More-
over, because of the variability of PD severity among affected individuals, we further 
hypothesize that cognitive measures are less likely to be correlated with disease dura-
tion: a patient with “mild disease” may have had PD for several years with minimal 
motor and, therefore, cognitive impairment; while a patient with an aggressive disease 
course may be signiﬁ  cantly impaired (physically and cognitively) sooner.
Methods
All patients diagnosed with “probable” PD at a single Movement Disorders Center 
were offered to undergo a comprehensive neuropsychological testing, regardless of 
their cognitive status. The results were correlated to the total motor score of the Uniﬁ  ed 
Parkinson Disease Rating Scale (UPDRS).
The diagnosis of “probable” PD, made by either of 3 fellowship-trained Movement 
Disorders Specialists (HHF, MSO, RLR), was determined by: (1) the presence of two 
out of three motor features of PD (tremor, rigidity, and bradykinesia), (2) and the 
absence of any features that would suggest other forms of Parkinsonism including lack 
of a substantial response to levadopa therapy. For all medicated patients, the UPDRS 
was performed in the “off” state (ie, at least 12 hours off all PD medications). There 
were no patients with deep brain stimulators included in our study.Neuropsychiatric Disease and Treatment 2007:3(6) 956
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The neuropsychological battery (performed in the “on” 
state, if medicated) included: the Mini-Mental Status Exam 
(MMSE); Dementia Rating Scale (DRS); and tests on the 
following domains: general intelligence (Wechsler Adult 
Intelligence Scale 3); academic performance (Wide Range 
Achievement Test-3 [WRAT-3]); attention and concentra-
tion (Digit Span); memory (Hopkins Verbal Learning Test 
[HVLT] and Weschler Memory Scale-III); language (Boston 
Naming, Controlled Oral Word Association Test); visual-
spatial skills (Judgment of Line Orientation [JOLO], Benton 
Facial Recognition Test); and executive function (Stroop, 
Trail Making Test).
Demographic data including age, disease duration and 
education were also obtained.
The correlation of the UPDRS motor scores to neuropsy-
chological performance (both raw scores and corrected scores 
for age and education) was then determined. Because some 
of the variables were found to deviate substantially from 
normality, nonparametric correlations (Spearman’s) were 
computed to examine the relationship between all variables. 
Since our study is exploratory, we did not apply a correction 
for multiple comparisons to determine signiﬁ  cance in our 
primary analyses. However, we indicated which correla-
tions remained signiﬁ  cant after a Bonferroni correction as a 
secondary analysis. To make sure that observed relationships 
were not solely due to the effects of intervening variables, 
multiple regressions were conducted to examine the unique 
relationship between motor and cognitive functioning after 
controlling for demographic characteristics and disease 
duration. All analyses were conducted with SPSS 13.0. 
The collection and utilization of data in this study is IRB 
approved.
Results
One hundred and six PD patients, 30 females and 76 males, 
were included in this study. Two participants were excluded 
based on very poor cognitive functioning (MMSE of 7 and 
14). The participants had an average: age of 67.1-years (SD: 
10.52); education of 14.75-years (SD: 3.38); disease dura-
tion of 110.41-months (SD: 74.43); MMSE score of 27.58 
(range: 18–30, SD: 2.45); and UPDRS motor “off ” score of 
38.40 (SD: 13.50). Only two patients were medication-naive 
in this cohort.
The tests that signiﬁ  cantly correlated with the UPDRS 
motor score were: MMSE, DRS, Digit Span, HVLT, 
WMS-III, Boston Naming Test, Letter Fluency, Animal 
Fluency, Stroop Color Naming and Trail Making Test B, rep-
resenting at least one component in the neuropsychological 
domains of attention and concentration, memory, language, 
and executive function (see Table 1). However, some tests 
under these cognitive domains did not correlate with the 
UPDRS motor score, including the Stroop word reading, 
Stroop color-word naming, and Trail Making Test A. Tests 
of general intelligence (WAIS-III), academic performance 
(WRAT-3), and visuospatial skills (JOLO and face recog-
nition) showed no signiﬁ  cant relationship with the UPDRS 
motor score.
Age, gender, and education were not significantly 
associated with the UPDRS motor score. Disease duration, 
however, was signiﬁ  cantly and positively correlated with 
UPDRS motor score (see Table 1). A multiple regression 
including UPDRS motor score and disease duration as 
independent predictors yielded UPDRS motor score as the 
sole unique predictor of MMSE (R2 = 0.09, F(2, 76) = 3.69, 
p  0.05, β (UPDRS) = –0.33, t  (76) = –2.71, p  0.01). 
Even as a single predictor, disease duration was not signiﬁ  -
cantly correlated with MMSE (r = –0.01, p  0.1, or DRS, 
r = –0.13, p  0.1).
Discussion
Our results showed a signiﬁ  cant correlation between the 
degree of motor impairment and most of the neuropsycho-
logical tests in all cognitive domains except for general 
intelligence and visuospatial function. This implies that the 
cognitive decline seen with PD is near ‘global’ rather than 
primarily being a ‘dysexecutive syndrome’ (Litvan et al 
1991). Moreover, although our study is cross-sectional, it 
suggests that cognitive decline tracks motor progression in 
PD although longitudinal studies are needed to conﬁ  rm this 
observation.
Although studies have found signiﬁ  cant visuospatial 
disturbances associated with PD (Huber et al 1989; Stern 
et al 1993), ours did not show a correlation between motor 
score and visuospatial abilities. This does not mean that 
visuospatial dysfunction did not occur in our cohort. This 
simply suggests that visuospatial dysfunction did not track 
motor progression. Possible explanations include: stron-
ger inﬂ  uence of external factors (eg, testing environment, 
medications) in visuospatial tests compared to measures of 
other cognitive domains; insensitivity of visuospatial tests 
used in this study; or, a difference or divergence in the etio-
pathogenesis of visual-spatial dysfunction in PD compared 
with the motor and other cognitive dysfunction. Also, it 
has been thought by some that visuospatial disturbances 
experienced by PD patients may be secondary to or at least 
inﬂ  uenced by executive dysfunction and inattention (Ogden Neuropsychiatric Disease and Treatment 2007:3(6) 957
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et al 1990; Bondi et al 1993). The visuospatial tests used 
in our study were not associated with the motor UPDRS 
scores, but representative tests of both executive function 
and attention were.
The correlation between the MMSE, representing 
the overall cognitive status, and the UPDRS motor score 
remained signiﬁ  cant even after controlling for disease dura-
tion. On the contrary, no correlation was found between 
disease duration and MMSE or DRS.
Several weaknesses in the study should be noted. The 
cohort consisted of patients treated at a single PD Center. 
Not all subjects agreed to be tested. We did not take note 
of the total number of subjects offered to undergo testing. 
It is therefore possible that patients with signs of dementia 
more likely agreed to undergo the neuropsychiatric evalu-
ation, contributing to a population bias. Also, patients with 
severe cognitive deﬁ  cits who were unable to complete the 
comprehensive neuropsychological examination (N = 2) 
were excluded. Nonetheless, we believe that this cohort 
represented a good spectrum of PD. The small number of 
excluded patients due to severe dementia (2/108) was not 
likely to inﬂ  uence overall results. Although our ‘convenience 
sample’ could be subject to population bias, the range 
in age (41–89), MMSE scores (18–30), disease duration 
(12 to 318-months), UPDRS scores (8–81), represented a 
wide PD spectrum.
All neuropsychological examination was performed in the 
“on” state. Thus, it is less likely that motor ﬂ  uctuations sig-
niﬁ  cantly contributed to their performance during cognitive 
testing. The motor UPDRS was obtained in the “off ” state 
to ensure uniformity, assess the true/baseline motor deﬁ  cits, 
without medication effect or the variability of its optimiza-
tion. Only 2 patients in our cohort were medication-naïve. 
Finally, this is a cross-sectional study so our data should be 
interpreted with caution.
In summary, the results of this study indicate that 
impairment in most cognitive domains correlate with motor 
symptoms in PD. Cognitive impairment may start early in the 
disease process but may be very mild and often undetected. 
While most clinicians are able to appreciate mild tremor or 
rigidity in one limb thereby easily “deﬁ  ning” the onset of 
motor dysfunction, the ﬁ  rst sign of cognitive impairment is 
Table 1 Nonparametric correlations between UPDRS scores and neuropsychological performance
  UPDRS total score
 Raw  scores    Corrected  scoresa
 R  p-valueb  R p-valueb
MMSE (N = 106)  −0.32  <0.001*  −  −
Dementia Rating Scale (N = 106)  −0.28  <0.01  −0.28  <0.01
WAIS-III Information (N = 102)  −0.14 0.15  −0.12 0.23
WAIS-III Vocabulary (N = 98)  −0.13 0.22  −0.13 0.21
Digit Span Total (N = 104)  −0.19  <0.05  −0.25  <0.01
Digit Span Forward (N = 104)  −0.16 0.11  −0.26  <0.01
Digit Span Backward (N = 104)  −0.06 0.58  −0.11 0.26
HVLT 1st trial (N = 104)  −0.27  <0.01  −0.30  <0.01*
HVLT Total (N = 104)  −0.23  <0.05  −0.27  <0.01
HVLT 20-minute Delay (N = 104)  −0.22  <0.05  −0.26  <0.01
HVLT Recognition (N = 104)  −0.26  <0.01  −0.30  <0.01
WMS-III Logical Memory I (N = 103)  −0.29  <0.01  −0.32  <0.001*
WMS-III Logical Memory II (N = 103)  −0.28  <0.01  −0.31  <0.01*
WRAT-3 Total (N = 98)  −0.06 0.58  −0.10 0.34
Boston Naming Test (N = 106)  −0.32  <0.001*  −0.31  <0.01*
Letter Fluency (N = 104)  −0.44  <0.001*  −0.42  <0.001*
Animal Fluency (N = 104)  −0.28  <0.01  −0.33  <0.001*
Judgment Of Line Orientation (N = 95)  −0.06 0.55  −0.15 0.16
Face Recognition Test (N = 98)  −0.15 0.15  −0.19 0.06
Stroop Word Reading (N = 100)  −0.10 0.34  −0.11 0.27
Stroop Color Naming (N = 93)  −0.21  <0.05  −0.23  <0.05
Stroop Color-Word Naming (N = 105)  −0.17 0.09  −0.19 0.06
Trail Making Test A (N = 102)  0.11  0.29  −0.16 0.12
Trail Making Test B (N = 98)  0.21  <0.05  −0.12 0.28
Disease Duration  0.46  <0.001*  −  −
Notes: aThis column refers to correlations between the UPDRS and age-corrected (WAIS-III Information and Vocabulary, Digit Span, HVLT, WMS-III Logical Memory, 
WRAT-3 and Stroop) or age-and-education corrected scores (Dementia Rating Scale, Boston Naming Test, Letter and Animal Fluency, Judgment of Line Orientation, Face 
Recognition Test and Trail Making Test A and B); bCorrelations that remained signiﬁ  cant after a Bonferroni correction (effective p-value = 0.002) are followed by a*.Neuropsychiatric Disease and Treatment 2007:3(6) 958
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more difﬁ  cult to identify. Longitudinal studies are needed to 
conﬁ  rm our results as our cross-sectional study can indicate 
correlation of cognitive impairment and motor symptoms, 
but is insufﬁ  cient to detect true parallel progression of cogni-
tive and motor impairment. If proven correct, then (1) better 
and practical cognitive tests sensitive to PD that mark the 
onset and track the progression of cognitive dysfunction 
are needed; and, (2) cognition enhancing or modifying 
(pharmacologic and non-pharmacologic) interventions, as 
they become available, should be considered early in the 
course of PD.
Finally, this study does not support previous reports 
regarding visuospatial impairment in PD. Controlled lon-
gitudinal studies with the use of more sensitive measures 
may be needed to deﬁ  ne the etiopathogenesis of visuospatial 
dysfunction in PD.
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